

Author  
Index

## A

- Abrahamson, D.** The borderline syndrome and affective disorders: A comment on the Wolf-Man, 6(4):549–551, 1980.
- Adler, S.A., Gottesman, I.I., Orsulak, P.J., Kizuka, P.P., and Schildkraut, J.J.** Platelet MAO activity: Relationships to clinical and psychometric variables, 6(2):226–231, 1980.
- Alpert, M., and Friedhoff, A.J.** An un-dopamine hypothesis of schizophrenia, 6(3):387–390, 1980.
- Anderson, C.M., Hogarty, G.E., and Reiss, D.J.** Family treatment of adult schizophrenic patients: A psycho-educational approach, 6(3):490–505, 1980.
- Angst, J., Felder, W., and Lohmeyer, B.** Course of schizoaffective psychoses: Results of a followup study, 6(4):579–585, 1980.
- Anr itto, W.J.** Schizophrenia and ego psychology, 7(2):199–200, 1981.
- Anonymous.** First person account: After the funny farm, 6(3):544–546, 1980.
- Anonymous.** First person account: Problems of living with schizophrenia, 7(1):196–197, 1981.
- Anonymous.** First person account: The quiet discrimination, 7(4):736–738, 1981.
- Arnold, F.; see Beck, J.C.**
- Arora, R.C.; see Meltzer, H.Y.**
- Aitchison, R.A.; see Wallace, C.J.**

## B

- Barry, R.J.; see James, A.L.**
- Beck, J.C., Golden, S., and Arnold, F.** An empirical investigation of psychotherapy with schizophrenic patients, 7(2):241–247, 1981.
- Beels, C.C.** Social support and schizophrenia, 7(1):58–72, 1981.
- Belmaker, R.H., Bracha, H.S., and Ebstein, R.P.** Platelet monoamine oxidase in affective illness and alcoholism, 6(2):320–323, 1980.
- Benedetti, G.** Individual psychotherapy or schizophrenia, 6(4):633–638, 1980.
- Benfield, T.C.; see Berrettini, W.H.**

- Berger, P.A., and Rexroth, K.** Tardive dyskinesia: Clinical, biological, and pharmacological perspectives, 6(1):102–116, 1980.
- Berner, P., Gabriel, E., and Schanda, H.** Nonschizophrenic paranoid syndromes, 6(4):627–632, 1980.
- Berrettini, W.H.; see Vogel, W.H.**
- Berrettini, W.H., Benfield, T.C., Schmidt, A.O., Ladman, R.K., and Vogel, W.H.** Platelet monoamine oxidase in families of chronic schizophrenics, 6(2):235–237, 1980.
- Blakar, R.M.** A comment on an abstract (letter), 7(1):206–207, 1981.
- Blashfield, R.K.; see Morey, L.C.**
- Bootzin, R.R.; see Shadish, W.R., Jr.**
- Bowers, M.B., Jr.** Biochemical processes in schizophrenia: An update, 6(3):393–403, 1980.
- Bracha, H.S.; see Belmaker, R.H.**
- Braff, D.L.** Impaired speed of information processing in non-medicated schizotypal patients, 7(3):499–508, 1981.
- Breakefield, X.O., and Edelstein, S.B.** Inherited levels of A and B types of monoamine oxidase activity, 6(2):282–288, 1980.
- Brey, K.H.** The mental hospital revisited: A program, 7(3):522–526, 1981.
- Bridge, T.P.; see Wise, C.D.**
- Bridge, T.P.; see Wyatt, R.J.**
- Brown, G.L.; see Langer, D.H.**
- Buchsbaum, M.S.; see Haier, R.J.**
- Buchsbaum, M.S.; see Puchall, L.B.**
- Buchsbaum, M.S., Coursey, R.D., and Murphy, D.L.** Schizophrenia and platelet monoamine oxidase: Research strategies, 6(2):375–384, 1980.
- Buckley, P.** Mystical experience and schizophrenia, 7(3):516–521, 1981.

## C

- Cannon-Spoor, H.E.; see Wise, C.D.**
- Cantor, S., Pearce, J., Pezzot-Pearce, T., and Evans, J.** The group of hypotonic schizophrenics, 7(1):1–11, 1981.
- Carling, P.J.** Nursing homes and chronic mental patients: A second opinion, 7(4):574–579, 1981.
- Cavenar, J.O.; see Sullivan, J.L.**
- Chan, C.; see Davis, J.M.**

- Chapman, J.P.; *see* Chapman, L.J.  
 Chapman, L.J., and Chapman, J.P. Scales for rating psychotic and psychotic-like experiences as continua, 6(3):476-489, 1980.
- Chapman, L.J., Edell, W.S., and Chapman, J.P. Physical anhedonia, perceptual aberration, and psychosis proneness, 6(4):639-653, 1980.
- Chaskel, R.; *see* Linden, M.
- Ciampi, L. Catamnestic long-term study on the course of life and aging of schizophrenics, 6(4):606-618, 1980.
- Coffey, C.E.; *see* Sullivan, J.L.
- Cohen, C.I.; *see* Lipton, F.R.
- Cohen, C.I.; *see* Sokolovsky, J.
- Cohen, D.J.; *see* Young, J.G.
- Corash, L. Platelet heterogeneity: Relevance to the use of platelets to study psychiatric disorders, 6(2):254-258, 1980.
- Corso, V.; *see* Nassar, P.
- Coursey, R.D.; *see* Buchsbaum, M.S.
- Coursey, R.D.; *see* Puchall, L.B.
- Cromwell, R.L., and Pithers, W.D. Schizophrenic/paranoid psychoses: Determining diagnostic divisions, 7(4):674-688, 1981.
- D**
- Davis, J.M.; *see* Zeller, E.A.
- Davis, J.M., Schaffer, C.B., Killian, G.A., Kinard, C., and Chan, C. Important issues in the drug treatment of schizophrenia, 6(1):70-87, 1980.
- Davis, K.L.; *see* Kendler, K.S.
- Dean, A.; *see* Lin, N.
- Dear, M.J.; *see* Taylor, S.M.
- DeMyer, M.K., Hingtgen, J.N., and Jackson, R.K. Infantile autism reviewed: A decade of research, 7(3):388-451, 1981.
- Dencker, S.J.; *see* Malm, U.
- Docherty, J.P.; *see* Langer, D.H.
- Dohrenwend, B.P., and Egri, G. Recent stressful life events and episodes of schizophrenia, 7(1):12-23, 1981.
- Domino, E.F. Monoamine oxidase substrates and substrate affinity, 6(2):292-297, 1980.
- Domino, E.F. Urinary acid metabolites of biogenic amines in schizo-

phrenic patients, 6(2):238-244, 1980.

## E

- Easton, K. Rehabilitation of the mentally ill (letter), 6(4):553-554, 1980.
- Ebstein, R.P.; *see* Belmaker, R.H.
- Edell, W.S.; *see* Chapman, L.J.
- Edelstein, S.B.; *see* Breakefield, X.O.
- Edwards, D.J. Molecular properties of the monoamine oxidases, 6(2):275-281, 1980.
- Egri, G.; *see* Dohrenwend, B.P.
- Elder, J.P.; *see* Wallace, C.J.
- Elston, R.C., and Nambodiri, K.K. Types of disease and models for their genetic analysis, 6(2):368-374, 1980.
- Ensel, W.M.; *see* Lin, N.
- Evans, J.; *see* Cantor, S.

## F

- Feiz, R.; *see* Young, J.G.
- Felder, W.; *see* Angst, J.
- Fenton, W.S., Mosher, L.R., and Matthews, S.M. Diagnosis of schizophrenia: A critical review of current diagnostic systems, 7(3):452-476, 1981.
- Ferris, C.; *see* Wallace, C.J.
- Fischer, E.; *see* Lipton, F.R.
- Forman, P.L.; *see* Koh, S.D.
- Friedhoff, A.J.; *see* Alpert, M.
- Friedhoff, A.J., and Miller, J.C. Platelet monoamine oxidase as a function of nongenetic factors, 6(2):314-319, 1980.
- Fryer, J.H.; *see* Prentky, R.A.

## G

- Gabriel, E.; *see* Berner, P.
- Garnezy, N. David Shakow, Ph.D., 1901-1981: In memoriam—Founder of modern clinical psychology, 7(3):385-387, 1981.
- Garrison, V., and Podell, J. "Community Support Systems Assessment" for use in clinical interviews, 7(1):101-108, 1981.
- Giller, E. Neuroleptic plasma levels and tardive dyskinesia (letter), 6(3):391, 1980.
- Goldberg, S.C. Drug and psychoso-

cial therapy in schizophrenia: Current status and research needs, 6(1):117-121, 1980.

- Golden, S.; *see* Beck, J.C.
- Gottesman, I.I.; *see* Adler, S.A.
- Grinker, R.R., Sr. Planning for a schizophrenic research program: A prototype, 7(1):181-195, 1981.
- Grinker, R.R., Sr.; *see* Koh, S.D.
- Gross, G.; *see* Huber, G.
- Grubb, T.W.; *see* Lewine, R.R.J.
- Gruzelier, J. Hemispheric imbalances masquerading as paranoid and nonparanoid syndromes? 7(4):662-673, 1981.
- Gunderson, J.G. A reevaluation of milieu therapy for nonchronic schizophrenic patients, 6(1):64-69, 1980.
- Guziec, R.J.; *see* Luria, R.E.

## H

- Haase, H. Followup treatment and aftercare of discharged schizophrenic patients, 6(4):619-626, 1980.
- Haier, R.J. The diagnosis of schizophrenia: A review of recent developments, 6(3):417-428, 1980.
- Haier, R.J., Buchsbaum, M.S., and Murphy, D.L. An 18-month followup of students biologically at risk for psychiatric problems, 6(2):334-337, 1980.
- Hammer, M. Social supports, social networks, and schizophrenia, 7(1):45-57, 1981.
- Hartmann, W., Kind, J., Meyer, J.E., Müller, P., and Steuber, H. Neuroleptic drugs and the prevention of relapse in schizophrenia: A workshop report, 6(3):536-543, 1980.
- Herzog, J.M.; *see* Schildkraut, J.J.
- Hingtgen, J.N.; *see* DeMyer, M.K.
- Hirsch, B.J. Coping and adaptation in high-risk populations: Toward an integrative model, 7(1):164-172, 1981.
- Hoffman, B.F. To tell or not to tell, 7(3):369-371, 1981.
- Hogarty, G.E.; *see* Anderson, C.M.
- Huber, G., Gross, G., Schüttler, R., and Linz, M. Longitudinal studies

- of schizophrenic patients, 6(4):592-605, 1980.
- Huesy, H.R.** Stress, social support, and schizophrenia: Discussion, 7(1):178-180, 1981.
- I**
- Iacono, W.G.;** see Lykken, D.T.
- J**
- Jackman, H.L., and Meltzer, H.Y.** Factors affecting determination of platelet monoamine oxidase activity, 6(2):259-266, 1980.
- Jackman, H.L.;** see Meltzer, H.Y.
- Jackson, R.K.;** see DeMyer, M.K.
- James, A.L., and Barry, R.J.** A review of psychophysiology in early onset psychosis, 6(3):506-525, 1980.
- K**
- Kalin, N.H.;** see Murphy, D.L.
- Katz, S.E.;** see Lipton, F.R.
- Keith, S.J.;** see Mosher, L.R.
- Kendler, K.S.** Are there delusions specific for paranoid disorders vs. schizophrenia? 6(1):1-3, 1980.
- Kendler, K.S., and Davis, K.L.** The genetics and biochemistry of paranoid schizophrenia and other paranoid psychoses, 7(4):689-709, 1981.
- Kendler, K.S., and Tsuang, M.T.** Nosology of paranoid schizophrenia and other paranoid psychoses, 7(4):594-610, 1981.
- Kessler, S.** The genetics of schizophrenia: A review, 6(3):404-416, 1980.
- Killian, G.A.;** see Davis, J.M.
- Kinard, C.;** see Davis, J.M.
- Kind, J.;** see Hartmann, W.
- Kizuka, P.P.;** see Adler, S.A.
- Klein, D.F.** Psychosocial treatment of schizophrenia, or psychosocial help for people with schizophrenia? 6(1):122-130, 1980.
- Klein, R.H.;** see Prentky, R.A.
- Koh, S.D., Grinker, R.R., Sr., Marusz, T.Z., and Forman, P.L.** Affective memory and schizophrenic anhedonia, 7(2):292-307, 1981.
- Kremberg, M.R.;** see Nassar, P.
- Kringlen, E.** Schizophrenia: Research in the Nordic countries, 6(4):566-578, 1980.
- Kroll, J., Pyle, R., Zander, J., Martin, K., Lari, S., and Sines, L.** Borderline personality disorder: Interrater reliability of the diagnostic interview for borderlines, 7(2):269-272, 1981.
- Kucharski, L.T., and Unterwald, E.M.** Symptomatic treatment of tardive dyskinesia: A word of caution, 7(4):571-573, 1981.
- L**
- Ladman, R.K.;** see Berrettini, W.H.
- Ladman, R.K.;** see Vogel, W.H.
- Langer, D.H., Brown, G.L., and Docherty, J.P.** Dopamine receptor supersensitivity and schizophrenia: A review, 7(2):208-224, 1981.
- Lari, S.;** see Kroll, J.
- Leff, J.P.;** see Vaughn, C.E.
- Lewine, R.R.J.;** see Prentky, R.A.
- Lewine, R.R.J., Watt, N.F., and Grubb, T.W.** High-risk-for-schizophrenia research: Sampling bias and its implications, 7(2):273-280, 1981.
- Liberman, R.P.;** see Wallace, C.J.
- Liem, J.H.** Family studies of schizophrenia: An update and commentary, 6(3):429-455, 1980.
- Lin, N., Dean, A., and Ensel, W.M.** Social support scales: A methodological note, 7(1):73-89, 1981.
- Linden, M., and Chaskel, R.** Information and consent in schizophrenic patients in long-term treatment, 7(3):372-378, 1981.
- Linz, M.;** see Huber, G.
- Lipton, F.R., Cohen, C.I., Fischer, E., and Katz, S.E.** Schizophrenia: A network crisis, 7(1):144-151, 1981.
- Lohmeyer, B.;** see Angst, J.
- Lovullo, W.R.;** see Sengel, R.A.
- Lukoff, D.;** see Wallace, C.J.
- Luria, R.E., and Guziec, R.J.** Comparative description of the SADS and PSE, 7(2):248-257, 1981.
- Lutz, J., and Marsh, T.K.** The effect of a dual level word list on schizophrenic free recall, 7(3):509-515, 1981.
- Lykken, D.T., Iacono, W.G., and Lykken, J.D.** Measuring deviant eye tracking, 7(2):204-205, 1981.
- Lykken, J.D.;** see Lykken, D.T.
- M**
- Magaro, P.A.** The paranoid and the schizophrenic: The case for distinct cognitive style, 7(4):632-661, 1981.
- Magaro, P.A.** Editorial introduction: The paranoid as an emerging character, 7(4):586-587, 1981.
- Mahorney, S.;** see Sullivan, J.L.
- Malm, U., May, P.R.A., and Dencker, S.J.** Evaluation of the quality of life of the schizophrenic outpatient: A checklist, 7(3):477-487, 1981.
- Mannuzza, S.** Cross-model reaction time and schizophrenic attentional deficit: A critical review, 6(4):654-675, 1980.
- Marsella, A.J., and Snyder, K.K.** Stress, social supports, and schizophrenic disorders: Toward an interactional model, 7(1):152-163, 1981.
- Marsh, A.** A psychofeedback approach to schizophrenia, 7(2):201-203, 1981.
- Marsh, T.K.;** see Lutz, J.
- Martin, K.;** see Kroll, J.
- Marusz, T.Z.;** see Koh, S.D.
- Matthews, S.M.;** see Fenton, W.S.
- May, P.R.A.;** see Malm, U.
- McFarlane, A.H.;** see Streiner, D.L.
- McFarlane, A.H., Neale, K.A., Norman, G.R., Roy, R.G., and Streiner, D.L.** Methodological issues in developing a scale to measure social support, 7(1):90-100, 1981.
- Meissner, W.W.** The schizophrenic and the paranoid process, 7(4):611-631, 1981.
- Meltzer, H.Y.** Relevance of dopamine autoreceptors for psychiatry: Pre-clinical and clinical studies, 6(3):456-475, 1980.
- Meltzer, H.Y.;** see Jackman, H.L.
- Meltzer, H.Y.;** see Mosher, L.R.
- Meltzer, H.Y.;** see Young, M.A.
- Meltzer, H.Y., Arora, R.C., Jackman, H., Pscheidt, G., and Smith, M.D.** Platelet monoamine oxidase and

plasma amine oxidase in psychiatric patients, 6(2):213-219, 1980.

Meltzer, H.Y., Jackman, H., and

Arora, R.C. Brain and skeletal muscle monoamine oxidase activity in schizophrenia, 6(2):208-212, 1980.

Meyer, J.E.; see Hartmann, W.

Miller, J.C.; see Friedhoff, H.J.

Minor, D. First person account: Third side of the coin, 7(2):316-317, 1981.

Morey, L.C., and Blashfield, R.K. A symptom analysis of the DSM-III definition of schizophrenia, 7(2):258-268, 1981.

Mosher, L.R.; see Fenton, W.S.

Mosher, L.R., and Keith, S.J. Psychosocial treatment: Individual, group, family, and community support approaches, 6(1):10-41, 1980.

Mosher, L.R., and Meltzer, H.Y. Drugs and psychosocial treatment: Editors' introduction, 6(1):8-9, 1980.

Müller, P.; see Hartmann, W.

Murphy, D.L.; see Buchsbaum, M.S.

Murphy, D.L.; see Haier, R.J.

Murphy, D.L.; see Puchall, L.B.

Murphy, D.L., and Kalin, N.H. Biological and behavioral consequences of alterations in monoamine oxidase activity, 6(2):355-367, 1980.

## N

Namoodiri, K.K.; see Elston, R.C.

Nasrallah, H.A. Neuroleptic plasma levels and tardive dyskinesia: The author replies (letter), 6(3):391-392, 1980.

Nasrallah, H.A. Neuroleptic plasma levels and tardive dyskinesia: A possible link? 6(1):4-7, 1980.

Nassar, P., Kremberg, M.R., and Corso, V. Inpatient art therapy: Implications and applications for training, 7(2):308-315, 1981.

Neale, K.A.; see McFarlane, A.H.

Nelson, C.J.; see Wallace, C.J.

Niederman, J.C.; see Shaskan, E.G.

Nies, A.; see Robinson, D.S.

Norman, G.R.; see McFarlane, A.H.

Norman, G.R.; see Streiner, D.L.

Nüsperli, M.; see Scharfetter, C.

## O

Orsulak, P.J.; see Adler, S.A.

Orsulak, P.J.; see Schildkraut, J.J.

## P

Parloff, M.B. David Shakow, Ph.D., 1901-1981: In memoriam—An extraordinary life, 7(3):383-384, 1981.

Pattison, E.M.; see Westermeyer, J.

Pattison, E.M., and Pattison, M.L. Analysis of a schizophrenic psychosocial network, 7(1):135-143, 1981.

Pattison, M.L.; see Pattison, E.M.

Pearce, J.; see Cantor, S.

Peske, M.A.; see Shaskan, E.G.

Pezot-Pearce, T.; see Cantor, S.

Phelps, B.H.; see Wise, C.D.

Phelps, B.H.; see Wyatt, R.J.

Phillips, S.L. Network characteristics related to the well-being of normals: A comparative base, 7(1):117-124, 1981.

Pilsecker, C. On educating schizophrenics about schizophrenia, 7(3):379-382, 1981.

Pithers, W.D.; see Cromwell, R.L.

Podell, J.; see Garrison, V.

Potkin, S.G.; see Wise, C.D.

Potkin, S.G.; see Wyatt, R.J.

Prentky, R.A., Lewine, R.R.J., Watt, N.F., and Fryer, J.H. A longitudinal study of psychiatric outcome: Developmental variables vs. psychiatric symptoms, 6(1):139-148, 1980.

Prentky, R.A., Salzman, L.F., and Klein, R.H. Habituation and conditioning of skin conductance responses in children at risk, 7(2):281-291, 1981.

Pscheidt, G.; see Meltzer, H.Y.

Puchall, L.B., Coursey, R.D., Buchsbaum, M.S., and Murphy, D.L. Parents of high risk subjects defined by levels of monoamine oxidase activity, 6(2):338-346, 1980.

Pyle, R.; see Kroll, J.

## R

Reiss, D.J.; see Anderson, C.M.

Rexroth, K.; see Berger, P.A.

Rinehart, K.; see Ritzler, B.A.

Ritzler, B.A. Paranoia—Prognosis and treatment: A review, 7(4):710-728, 1981.

Ritzler, B.A., and Rinehart, K. Psychotic controls in schizophrenia research, 7(4):729-735, 1981.

Robinson, D.S., and Nies, A. Demographic, biologic, and other variables affecting monoamine oxidase activity, 6(2):298-307, 1980.

Roth, J.A.; see Young, J.G.

Roy, R.G.; see McFarlane, A.H.

Roy, R.G.; see Streiner, D.L.

## S

Salzman, L.F.; see Prentky, R.A.

Schaffer, C.B.; see Davis, J.M.

Schanda, H.; see Berner, P.

Scharfetter, C., and Nüsperli, M. The group of schizophrenias, schizoaffective psychoses, and affective disorders, 6(4):586-591, 1980.

Schatzberg, A.F.; see Schildkraut, J.J.

Schildkraut, J.J.; see Adler, S.A.

Schildkraut, J.J., Orsulak, P.J., Schatzberg, A.F., and Herzog, J.M. Platelet monoamine oxidase activity in subgroups of schizophrenic disorders, 6(2):220-225, 1980.

Schmidt, A.O.; see Berrettini, W.H.

Schooler, N.R. Neuroleptics and psychosocial treatments: A discussion, 6(1):131-134, 1980.

Schulsinger, F. Schizophrenia in Europe: Editor's introduction, 6(4):555, 1980.

Schulz, C.G. Discussion of neuroleptics and psychosocial treatment, 6(1):135-138, 1980.

Schüttler, R.; see Huber, G.

Sengel, R.A., and Lovallo, W.R. A random process model of cognitive deficit in schizophrenia, 6(3):526-535, 1980.

Shadish, W.R., Jr., and Bootzin, R.R. Long-term community care: Mental health policy in the face of reality, 7(4):580-585, 1981.

Shadish, W.R., Jr., and Bootzin, R.R. Nursing homes and chronic mental patients, 7(3):488-498, 1981.

Shakow, D. Kent-Rosanoff Association and its implications for seg-

- mental set theory, 6(4):676-685, 1980.
- Shaskan, E.G., Peszke, M.A., and Niederman, J.C.** Studies of platelet monoamine oxidase activity in Epstein-Barr and Dengue virus infections, 6(2):347-354, 1980.
- Sines, L.;** see Kroll, J.
- Smith, M.D.;** see Meltzer, H.Y.
- Snyder, K.K.;** see Marsella, A.J.
- Sokolovsky, J., and Cohen, C.I.** Toward a resolution of methodological dilemmas in network mapping, 7(1):109-116, 1981.
- Sourkes, T.L.** Some current matters of monoamine oxidase biochemistry, 6(2):289-291, 1980.
- Spring, B.** Stress and schizophrenia: Some definitional issues, 7(1):24-33, 1981.
- Steuber, H.;** see Hartmann, W.
- Streiner, D.L.;** see McFarlane, A.H.
- Streiner, D.L., Norman, G.R., McFarlane, A.H., and Roy, R.G.** Quality of life events and their relationship to strain, 7(1):34-42, 1981.
- Sullivan, J.L., Coffey, C.E., Sullivan, P.D., Taska, R., Mahorney, S., and Cavenar, J.O.** Metabolic factors affecting monoamine oxidase activity, 6(2):308-313, 1980.
- Sullivan, P.D.;** see Sullivan, J.L.
- T**
- Taska, R.;** see Sullivan, J.L.
- Taylor, S.M., and Dear, M.J.** Scaling community attitudes toward the mentally ill, 7(2):225-240, 1981.
- Torrey, E.F.** The epidemiology of paranoid schizophrenia, 7(4):588-593, 1981.
- Tsuang, M.T.;** see Kendler, K.S.
- Turkat, D.** Training in community support development (letter), 6(4):552-553, 1980.
- U**
- Unterwald, E.M.;** see Kucharski, L.T.
- V**
- Vaughn, C.E., and Leff, J.P.** Patterns of emotional response in relatives of schizophrenic patients, 7(1):43-44, 1981.
- Vogel, W.H.;** see Berrettini, W.H.
- Vogel, W.H., Ladman, R.K., and Berrettini, W.H.** Further studies on the endogenous inhibitor of monoamine oxidase in schizophrenic plasma, 6(2):232-234, 1980.
- W**
- Waldo, M.C.;** see Young, J.G.
- Wallace, C.J., Nelson, C.J., Liberman, R.P., Aitchison, R.A., Lukoff, D., Elder, J.P., and Ferris, C.** A review and critique of social skills training with schizophrenic patients, 6(1):42-63, 1980.
- Watt, N.F.;** see Lewine, R.R.J.
- Watt, N.F.;** see Prentky, R.A.
- Westermeyer, J., and Pattison, E.M.** Social networks and mental illness in a peasant society, 7(1):125-134, 1981.
- Wing, J.K.** Social psychiatry in the United Kingdom: The approach to schizophrenia, 6(4):556-565, 1980.
- Wise, C.D.;** see Wyatt, R.J.
- Wise, C.D., Potkin, S.G., Bridge, T.P., Phelps, B.H., Cannon-Spoor, H.E., and Wyatt, R.J.** Sources of error in the determination of platelet monoamine oxidase: A review of methods, 6(2):245-253, 1980.
- Wolfe, A.W.** Stress, social support, and schizophrenia: Discussion, 7(1):173-177, 1981.
- Wyatt, R.J.;** see Wise, C.D.
- Wyatt, R.J., Potkin, S.G., Bridge, T.P., Phelps, B.H., and Wise, C.D.** Monoamine oxidase in schizophrenia: An overview, 6(2):199-207, 1980.
- Y**
- Young, J.G., Cohen, D.J., Waldo, M.C., Feiz, R., and Roth, J.A.** Platelet monoamine oxidase activity in children and adolescents with psychiatric disorders, 6(2):324-333, 1980.
- Young, M.A., and Meltzer, H.Y.** The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements, 6(1):88-101, 1980.
- Z**
- Zander, J.;** see Kroll, J.
- Zeller, E.A., and Davis, J.M.** Protein content and monoamine oxidase activity in platelets, 6(2):267-274, 1980.
- Zelt, D.** First person account: The messiah quest, 7(3):527-531, 1981.



## Subject Index

### A

**Adoptive studies.** *See* Family studies.

#### Affective disorders

Affective illness and platelet MAO activity [Robinson], 6(2):298-307, 1980; [Belmaker], 6(2):320-323, 1980; [Haier], 6(2):334-337, 1980; [Puchall], 6(2):338-346, 1980.

Affective symptomatology in biological "risk" sample [Haier], 6(2):334-337, 1980.

Course of bipolars compared to schizoaffective disorders [Angst], 6(4):579-585, 1980.

Family-genetic studies of bipolar and unipolar disorders [Scharfetter], 6(4): 586-591, 1980.

Postpsychotic and drug-induced depressions [Hartmann], 6(3):536-543, 1980.

Relationship of social support and stressful life events to depression in community survey [Lin], 7(1):73-89, 1981.

**Aftercare.** *See* Community psychiatry.

#### Age

Effects on MAO activity [Robinson], 6(2):298-307, 1980; [Young], 6(2):324-333, 1980.

Elderly patients' course of psychosis [Ciompi], 6(4):606-618, 1980.

#### Amphetamine psychosis

As a pharmacological model of schizophrenia [Alpert], 6(3):387-390, 1980.

#### Anhedonia, physical

In sample of schizotypal college students [Chapman], 6(3):476-489, 1980; [Chapman], 6(4):639-653, 1980.

#### Anhedonia, schizophrenic

Mnemonic processing and [Koh], 7(2):292-307, 1981.

#### Art therapy

In groups of acute inpatients [Nassar], 7(2):308-315, 1981.

**Attention.** *See also* Cognition; Information processing.

Cross-modal reaction time

[Mannuzza], 6(4):654-675, 1980.

Implications of word association performance for theory of segmental set [Shakow], 6(4): 676-685, 1980.

In schizophrenic and schizotypal patients [Braff], 7(3):499-508, 1981.

**Autism.** *See* Infantile autism.

#### Autobiographical accounts

Description of psychiatric hospitalization and experiences after discharge [Anonymous], 6(3):544-546, 1980.

Discrimination against recovered patients [Anonymous], 7(4):736-738, 1981.

Experience of acute psychosis described as "Messiah quest" [Zelt], 7(3):527-531, 1981.

Mystical experience [Buckley], 7(3):516-521, 1981.

Postillness adjustment and acceptance of illness [Minor], 7(2):316-317, 1981.

Problems of living with schizophrenia [Anonymous], 7(1):196-197, 1981.

### B

#### Behavioral/educational treatment

Infantile autism and other disorders of childhood [DeMyer], 7(3):388-451, 1981.

Psycho-educational family intervention strategy [Anderson], 6(3):490-505, 1980.

Social skills training [Wallace], 6(1):42-63, 1980.

#### Biochemical factors in schizophrenia.

*See also* Biological factors in schizophrenia; Dopamine; Genetics; Monoamine oxidase.

Amphetamine model psychosis [Alpert], 6(3):387-390, 1980.

Creatine phosphokinase [Bowers], 6(3):393-403, 1980.

Endorphins [Bowers], 6(3):393-403, 1980.

In paranoid schizophrenia [Kendler], 7(4):689-709, 1981.

In schizophrenic disorders of childhood [DeMyer], 7(3):388-451, 1981.

Research in Nordic countries [Kringlen], 6(4):566-578, 1980.

### Biological factors in schizophrenia

Immunologic and viral factors [Bowers], 6(3):393-403, 1980.

**Bipolar depression.** *See* Affective disorders.

### Borderline personality disorder

Interrater reliability of the Diagnostic Interview for Borderlines (DIB) [Kroll], 7(2):269-272, 1981.

### Borderline schizophrenia

In Nordic psychiatry [Kringlen], 6(4):566-578, 1980.

### Borderline syndrome

Relationship to affective disorders, illustrated by the Wolf-man case [Abrahamson], 6(4):549-551, 1980.

## C

### Catatonia

Family-genetic study [Scharfetter], 6(4):586-591, 1980.

**Childhood psychoses.** *See* Infantile autism; Pervasive developmental disorders.

### Children and adolescents with psychiatric disorders

Hypotonic subgroup [Cantor], 7(1):1-11, 1981.  
Platelet MAO activity in [Young], 6(2):324-333, 1980.

**Children at risk for schizophrenia.** *See* High-risk studies.

### Chronic schizophrenia

Assessed in longitudinal study of large cohort [Huber], 6(4):592-605, 1980; [Ciampi], 6(4):606-618, 1980.

Factors maintaining disabilities and policy questions concerning [Wing], 6(4):556-565, 1980; [Shadish], 7(3):488-498, 1981;

(discussion) [Carling], 7(4):574-579, 1981; (rejoinder) [Shadish], 7(4):580-585, 1981.

Pharmacotherapy [Davis], 6(1):70-87, 1980; [Hartmann], 6(3):536-543, 1980; [Haase], 6(4):619-626, 1980.

Psychosocial treatment [Mosher], 6(1):10-41, 1980; [Haase], 6(4):619-626, 1980.

Reduction of platelet MAO activity in [Wyatt], 6(2):199-207, 1980; [Bowers], 6(3):393-403, 1980.

**Cognition.** *See also* Attention; Information processing; Mnemonic processing.

In paranoid vs. nonparanoid schizophrenia [Meissner], 7(4):611-631, 1981; [Magaro], 7(4):632-661, 1981; [Cromwell], 7(4):674-688, 1981.

Random process model of cognitive deficit in schizophrenia [Sengel], 6(3):526-535, 1980.

### Communication patterns

Deviance in families of schizophrenics [Liem], 6(3):429-455, 1980.

### Community attitudes toward the mentally ill

Survey conducted in Metropolitan Toronto using the CAMI scales [Taylor], 7(2):255-240, 1981.

### Community psychiatry

Checklist to assess quality of life of discharged patients [Malm], 7(3):477-487, 1981.

Historical development in United Kingdom [Wing], 6(4):556-565, 1980.

Nursing homes' role in community-based care [Shadish], 7(3):488-498, 1981; (discussion) [Carling], 7(4):574-579, 1981; (rejoinder) [Shadish], 7(4):580-585, 1981.

**Community support systems.** *See also* Social support systems.

As treatment of schizophrenia [Mosher], 6(1):10-41, 1980;

(discussion) [Klein], 6(1):122-130, 1980.

Assessment interview for use in clinical setting [Garrison], 7(1):101-108, 1981.

Training conference for mental health service providers (letter) [Turkat], 6(4):552-553, 1980.

**Creatine phosphokinase.** *See* Biochemical factors in schizophrenia.

## D

**Deinstitutionalization.** *See also* Community psychiatry; Community support systems.

Problems in (letter) [Easton], 6(4):553-554, 1980; [Shadish], 7(3):488-498, 1981; (discussion) [Carling], 7(4):574-579, 1981; (rejoinder) [Shadish], 7(4):580-585, 1981.

**Depression.** *See* Affective disorders.

### Diagnosis

Borderline schizophrenia [Kringlen], 6(4):566-578, 1980.

Differential diagnosis of paranoid schizophrenia and paranoid psychoses [Kendler], 7(4):594-610, 1981.

How and when to tell the patient of a diagnosis of schizophrenia [Hoffman], 7(3):369-371, 1981.

Paranoid states [Kendler], 6(1):1-3, 1980.

Present State Examination and SADS structured interviews compared [Luria], 7(2):248-257, 1981.

Reliability and validity of current research diagnostic systems [Fenton], 7(3):452-476, 1981.

Schizophrenia compared with manic-depression, schizoaffective disorder, and borderline schizophrenia [Haier], 6(3):417-428, 1980.

Schizophreniform psychoses [Kringlen], 6(4):566-578, 1980.

Symptom analysis of DSM-III definition of schizophrenia [Morey], 7(2):258-268, 1981.

Use of biological measures in [Haier], 6(3):417-428, 1980;

[Gruzelier], 7(4):662-673, 1981.  
Wolf-man case [Abrahamson],  
6(4):549-551, 1980.

### Diagnostic criteria

Diagnostic interview for Borderlines  
[Kroll], 7(2):269-272, 1981.  
DSM-III [Kendler], 6(1):1-3, 1980;  
[Haier], 6(3):417-428, 1980;  
[Morey], 7(2):258-268, 1981;  
[DeMyer], 7(3):388-451, 1981;  
[Fenton], 7(3):452-476, 1981;  
[Kendler], 7(4):594-610, 1981.  
Feighner criteria [Fenton],  
7(3):452-476, 1981.  
Flexible system [Fenton],  
7(3):452-476, 1981.  
Maine Paranoid-Schizophrenic Rat-  
ing Scale [Magaro], 7(4):632-661,  
1981.  
New Haven Schizophrenia Index  
[Fenton], 7(3):452-476, 1981.  
Present State Examination [Haier],  
6(3):417-428, 1980; [Luria], 7(2):  
248-257, 1981.  
Research Diagnostic Criteria [Haier],  
6(2):334-337, 1980; [Puchall],  
6(2):338-346, 1980; [Haier],  
6(3):417-428, 1980; [Luria],  
7(2):248-257, 1981; [Fenton],  
7(3):452-476, 1981.  
Schizophrenia State Inventory  
[Grinker], 7(1):181-195, 1981.  
Schneider's first-rank symptoms  
[Fenton], 7(3):452-476, 1981.

### Dopamine

Autoreceptors [Meltzer],  
6(3):456-475, 1980.  
Hypothesis of schizophrenia  
[Alpert], 6(3):387-390, 1980;  
[Bowers], 6(3):393-403, 1980.  
Receptor sensitivity [Langer],  
7(2):208-224, 1981.

### Drug therapy. See Pharmacotherapy.

### Dyskinesia, tardive

Abnormal Involuntary Movements  
Scale (AIMS) [Berger],  
6(1):102-116, 1980.  
Characteristics, differential diagno-  
sis, neuropathology, pharmacolo-  
gy, and prevalence (literature re-  
view) [Berger], 6(1):102-116,  
1980.

Dopamine autoreceptors and  
[Meltzer], 6(3):456-475, 1980.  
Need for caution in symptomatic  
treatment of [Kucharski],  
7(4):571-573, 1981.  
Neuroleptic plasma levels and  
[Nasrallah], 6(1):4-7, 1980; (let-  
ter) [Giller], 6(3):391, 1980; (let-  
ter) [Nasrallah], 6(3):391-392,  
1980.

## E

Early onset psychosis. *see* Infantile  
autism.

### Electroencephalogram (EEG)

Findings in infantile autism  
[James], 6(3):506-525, 1980.

Endorphins. *See* Biochemical factors  
in schizophrenia.

### Epidemiology

Paranoid schizophrenia [Torrey],  
7(4):588-593, 1981.

European contributions to study of  
schizophrenia [Schulsinger],  
6(4):555, 1980; [Wing], 6(4):556-565,  
1980; [Kringlen], 6(4):566-578, 1980;  
[Angst], 6(4):579-585, 1980;  
[Scharfetter], 6(4):586-591, 1980;  
[Huber], 6(4):592-605, 1980;  
[Ciampi], 6(4):606-618, 1980;  
[Haase], 6(4):619-626, 1980;  
[Berner], 6(4):627-632, 1980;  
[Benedetti], 6(4):633-638, 1980.

### Evoked potentials

Augmenting/reducing measure in  
student population at "biologi-  
cal" risk [Haier], 6(2):334-337,  
1980.  
In infantile autism [James],  
6(3):506-525, 1980.

### Expressed emotion (EE)

In relatives of schizophrenic pa-  
tients [Vaughn], 7(1):43-44, 1981.

### Eye tracking

Comparison of measurement tech-  
niques [Lykken], 7(2):204-205,  
1981.

## F

### Family studies

Adoption studies [Kessler],  
6(3):404-416, 1980; [Kringlen],  
6(4):566-578, 1980.  
Affective psychopathology and alco-  
holism in parents of low and high  
MAO college students [Puchall],  
6(2):338-346, 1980.  
Consanguinity studies of role of ge-  
netic factors in transmission of  
schizophrenia [Kessler],  
6(3):404-416, 1980.  
Disordered family communication  
[Liem], 6(3):429-455, 1980; (letter)  
[Blakar], 7(2):206-207, 1981.  
Expressed emotion (EE) in relatives  
of schizophrenics [Vaughn],  
7(1):43-44, 1981.  
Family-genetic studies of affective  
psychoses and subtypes of schiz-  
ophrenia [Scharfetter],  
6(4):586-591, 1980.  
Family role relationships [Liem],  
6(3):429-455, 1980.  
In Nordic countries [Kringlen],  
6(4):566-578, 1980.  
Lower  $V_{max}$  and  $K_m$  values for plate-  
let MAO activity in relatives of  
chronic schizophrenics  
[Berrettini], 6(2):235-237, 1980.

### Family treatment

Effectiveness in schizophrenia (lit-  
erature view) [Mosher],  
6(1):10-41, 1980; (discussion)  
[Klein], 6(1):122-130, 1980.  
Network intervention used in case  
study of schizophrenic girl  
[Pattison], 7(1):135-143, 1981.  
Psycho-educational approach to re-  
duction of family stress  
[Anderson], 6(3):490-505, 1980.

### Freud

Theories of schizophrenia  
[Meissner], 7(4):611-631, 1981.  
Wolf-man case [Abrahamson],  
6(4):549-551, 1980.

## G

Genetic counseling [Kessler],  
6(3):404-416, 1980.



## Genetics

- Consanguinity, twin, and adoptive studies of genetic transmission in schizophrenia [Kessler], 6(3):404-416, 1980.
- Family-genetic study of affective psychoses and subtypes of schizophrenia [Scharfetter], 6(4):586-591, 1980.
- Infantile autism [DeMyer], 7(3):388-451, 1981.
- Models of genetic analysis in single large pedigrees [Elston], 6(2):368-374, 1980.
- Monoamine oxidase activity [Berrettini], 6(2):235-237, 1980; [Breakefield], 6(2):282-288, 1980; [Elston], 6(2):368-374, 1980.
- Paranoid psychoses and paranoid schizophrenia [Kendler], 7(4):689-709, 1981.
- Relationship to research diagnostic systems [Fenton], 7(3):452-476, 1981.

## Group therapy

- Art therapy groups [Nassar], 7(2):308-315, 1981.
- Effectiveness in schizophrenia (literature review) [Mosher], 6(1):10-41, 1980; (discussion) [Klein], 6(1):122-130, 1980.

## H

### Hallucinations

- Correlation with low MAO activity [Wyatt], 6(2):199-207, 1980; [Meltzer], 6(2):213-219, 1980; [Schildkraut], 6(2):220-225, 1980; [Adler], 6(2):226-231, 1980.
- Critique of ego psychological interpretation [Annitto], 7(2):199-200, 1981; (rejoinder) [Marsh], 7(2):201-203, 1981.

### Hebephrenia

- Family-genetic study [Scharfetter], 6(4):586-591, 1980.

### Hemispheric processing

- In paranoid and nonparanoid schizophrenia [Magaro], 7(4):632-661, 1981; [Gruzelier], 7(4):662-673, 1981; [Cromwell], 7(4):674-688, 1981.

**Heredity.** See Family studies; Genetics; Twin studies.

### High-risk studies

- Followup of college students in a "biological high-risk" sample [Haier], 6(2):334-337, 1980.
- In Nordic countries [Kringlen], 6(4):566-578, 1980.
- Physical anhedonia and perceptual aberrations as subject selection criteria [Chapman], 6(3):476-489, 1980; [Chapman], 6(4):639-653, 1980.
- Psychopathology in parents of college students at "biological" risk [Puchall], 6(2):338-346, 1980.
- Sampling bias in [Lewine], 7(2):273-280, 1981.
- Skin conductance responses in children at risk [Prentky], 7(2):281-291, 1981.
- Social networks and coping strategies in high-risk populations [Hirsch], 7(1):164-172, 1981.

## I

**Immunologic factors.** See Biological factors in schizophrenia.

**Infantile autism.** See also Children and adolescents with psychiatric disorders.

- Platelet MAO activity in [Young], 6(2):324-333, 1980.
- Psychophysiology, EEG, and evoked potential findings [James], 6(3):506-525, 1980.
- Research on etiology, diagnosis, prognosis, and treatment (literature review) [DeMyer], 7(3):388-451, 1981.

**Information processing.** See also Attention; Cognition; Mnemonic processing.

- In paranoid schizophrenia and nonparanoid schizophrenia [Meissner], 7(4):611-631, 1981; [Magaro], 7(4):632-661, 1981; [Cromwell], 7(4):674-688, 1981.
- In schizophrenics and schizotypals [Braff], 7(3):499-508, 1981.

## K

### Kent-Rosanoff Association Test

- Implications for theory of segmental set [Shakow], 6(4):676-685, 1980.

## L

**Laterality.** See Hemispheric processing.

**Life events.** See also Stressful life events.

- Community survey assessing relation to depression [Lin], 7(1):73-89, 1981.
- Relationship of positive and negative events to strain [Streiner], 7(1):34-42, 1981.

## M

**Memory.** See Mnemonic processing.

### Mental retardation

- Compared to infantile autism and other childhood disorders [DeMyer], 7(3):388-451, 1981.

### Milieu therapy

- Effectiveness with nonchronic schizophrenic patients (review [Gunderson], 6(1):64-69, 1980.

### Minnesota Multiphasic Personality Inventory (MMPI)

- Aberrant profiles used to generate sample for biological studies [Haier], 6(2):334-337, 1980.

### Mnemonic processing

- Effect of dual-level word list on free recall [Lutz], 7(3):509-515, 1981.
- In nonparanoid schizophrenia [Magaro], 7(4):632-661, 1981.
- Schizophrenic anhedonia and [Koh], 7(2):292-307, 1981.

### Monoamine oxidase (MAO)

- Affective illness relationship to [Belmaker], 6(2):320-323, 1980.
- Affective psychopathology in parents of low and high MAO college students [Puchall], 6(2):338-346, 1980.

- Age relationships to [Robinson], 6(2):298-307, 1980; [Young], 6(2):324-333, 1980.
- Alcoholism relationship to [Adler], 6(2):226-231, 1980; [Belmaker], 6(2):320-323, 1980; [Puchall], 6(2):338-346, 1980.
- Assay reliability [Jackman], 6(2):259-266, 1980.
- Basic biochemistry of [Sourkes], 6(2):289-291, 1980.
- Biological and behavioral consequences of alterations in activity [Murphy], 6(2):355-367, 1980.
- Brain MAO in schizophrenia [Meltzer], 6(2):208-212, 1980; [Robinson], 6(2):298-307, 1980.
- Corash method for preparation of total whole blood platelets [Wise], 6(2):245-253, 1980; [Corash], 6(2):254-258, 1980.
- Diabetes and [Zeller], 6(2):267-274, 1980.
- Dietary factors and [Sullivan], 6(2):303-313, 1980.
- Differential centrifugation method [Jackman], 6(2):259-266, 1980; [Wise], 6(2):245-253, 1980.
- Dyslexia and [Zeller], 6(2):267-274, 1980.
- Effects of inhibition on neuronal function and monoamine metabolism [Murphy], 6(2):355-367, 1980.
- Endogenous inhibitor of [Vogel], 6(2):232-234, 1980.
- Epstein-Barr and Dengue virus infections and [Shaskan], 6(2):347-354, 1980.
- Genetic analysis of schizophrenia and MAO activity [Elston], 6(2):368-374, 1980.
- Genetic factors controlling levels of A and B types of MAO activity [Breakefield], 6(2):282-288, 1980.
- Hallucinations and [Meltzer], 6(2):208-212, 1980; [Schildkraut], 6(2):220-225, 1980; [Adler], 6(2):226-231, 1980.
- Heavy vs. light platelet fractions [Friedhoff], 6(2):314-319, 1980.
- Hormonal factors and [Sullivan], 6(2):303-313, 1980.
- Immunologic factors and [Shaskan], 6(2):347-354, 1980.
- In autism [Young], 6(2):324-333, 1980.
- In children and adolescents with psychiatric illness [Young], 6(2):324-333, 1980.
- In depressed outpatients [Robinson], 6(2):298-307, 1980.
- In schizophrenia-related depressions [Schildkraut], 6(2):220-225, 1980.
- In students with aberrant MMPI profiles [Haier], 6(2):334-337, 1980.
- Lower  $K_m$  and  $V_{max}$  in first-degree relatives of chronic schizophrenics [Berrettini], 6(2):235-237, 1980.
- Methodology for determination of platelet MAO activity [Wise], 6(2):245-253, 1980; [Corash], 6(2):254-258, 1980; [Jackman], 6(2):259-266, 1980.
- Molecular properties [Edwards], 6(2):275-281, 1981.
- Neuroleptic treatment effect [Jackman], 6(2):259-266, 1980; [Friedhoff], 6(2):314-319, 1980.
- Paranoia and [Wyatt], 6(2):199-207, 1980; [Schildkraut], 6(2):220-225, 1980; [Kendler], 7(4):689-709, 1981.
- Parkinson's disease and [Zeller], 6(2):267-274, 1980.
- Physiologic consequences of MAO inhibition in man and animals [Murphy], 6(2):355-367, 1980.
- Plasma amine oxidase and platelet MAO in psychiatric patients [Meltzer], 6(2):208-212, 1980.
- Platelet count and platelet protein methods compared [Jackman], 6(2):259-266, 1980.
- Platelet heterogeneity [Corash], 6(2):254-258, 1980.
- Platelet volume, platelet protein densities, and protein content per platelet [Friedhoff], 6(2):314-319, 1980.
- Protein content and MAO [Zeller], 6(2):267-274, 1980.
- Relationship to evoked potential augmenting/reducing in population of college students at "biological risk" [Haier], 6(2):334-337, 1980.
- Research strategies [Buchsbaum], 6(2):375-384, 1980.
- Riboflavin and iron influence on MAO activity [Sourkes], 6(2):289-291, 1980; [Sullivan], 6(2):308-313, 1980.
- Role in schizophrenia [Bowers], 6(3):393-403, 1980; (review) [Wyatt], 6(2):199-207, 1980.
- Selective inhibitors of MAO type A and B [Murphy], 6(2):355-367, 1980.
- Sex differences [Robinson], 6(2):298-307, 1980.
- Skeletal muscle [Meltzer], 6(2):208-212, 1980.
- Social introversion and [Adler], 6(2):226-231, 1980.
- Substrates and substrate affinity [Domino], 6(2):292-297, 1980.
- Types A and B [Edwards], 6(2):275-281, 1980.
- Type B MAO amine substrates [Domino], 6(2):292-297, 1980.
- Mystical experience**
- Compared in schizophrenia and mystical religious states [Buckley], 7(3):516-521, 1981.
- N**
- National Institute of Mental Health (NIMH)**
- Schizophrenia-related research grants, fiscal year 1979, 7(2):318-365, 1981.
- Neuroleptics. See also**
- Pharmacotherapy; Biochemical factors in schizophrenia.
- Effect on platelet MAO activity [Jackman], 6(2):259-266, 1980; [Friedhoff], 6(2):314-319, 1980.
- Tardive dyskinesia and [Nasrallah], 6(1):4-7, 1980; [Davis], 6(1):70-87, 1980; [Berger], 6(1):102-116, 1980; [Goldberg], 6(1):117-121, 1980; (letter) [Giller], 6(3):391, 1980; (letter) [Nasrallah], 6(3):391-392, 1980.
- Nursing Homes**
- Role in care of schizophrenic patients discharged from mental

hospitals [Shadish], 7(3):488-498, 1981; (discussion) [Carling], 7(4):574-579, 1981; (rejoinder) [Shadish], 7(4):580-585, 1981.

## O

### Outcome

- Developmental variables and premorbid adjustment as predictors of [Prentky], 6(1):139-148, 1980.
- In nonschizophrenic paranoid syndromes [Berner], 6(4):627-632, 1980.
- In Nordic countries [Kringlen], 6(4):566-578, 1980.
- In old age [Ciampi], 6(4):606-618, 1980.
- In paranoia [Kendler], 6(1):1-3, 1980; [Kendler], 7(4):594-610, 1981; [Ritzler], 7(4):710-728, 1981.
- Longitudinal studies [Huber], 6(4):592-605, 1980; [Ciampi], 6(4):606-618, 1980; [Berner], 6(4):627-632, 1980.
- Psychiatric symptoms at first admission as predictors of [Prentky], 6(1):139-148, 1980.
- Social and symptomatic outcome [Huber], 6(4):592-605, 1980.

## P

### Paranoia

- Biochemical findings concerning [Wyatt], 6(2):199-207, 1980; [Schildkraut], 6(2):220-225, 1980; [Kendler], 7(4):689-709, 1981.
- Catamnestic findings of followup investigations of paranoid syndromes [Berner], 6(4):627-632, 1980.
- Cognitive style characteristic of [Meissner], 7(4):611-631, 1981; [Magaro], 7(4):632-661, 1981; [Cromwell], 7(4):674-688, 1981.
- Delusions of jealousy in [Kendler], 6(1):1-3, 1980; [Kendler], 7(4):594-610, 1981.
- Differential diagnosis of paranoid schizophrenia and other paranoid disorders [Kendler], 6(1):1-3, 1980; [Kendler], 7(4):594-610, 1981; [Meissner], 7(4):611-631,

1981; [Magaro], 7(4):632-661, 1981; [Cromwell], 7(4):674-688, 1981.

Epidemiologic evidence concerning [Torrey], 7(4):588-593, 1981.

Family-genetic study [Scharfetter], 6(4):586-591, 1980.

Genetic findings concerning [Kendler], 7(4):689-709, 1981.

Hemispheric processing and [Magaro], 7(4):632-661, 1981; [Gruzelier], 7(4):662-673, 1981.

Paranoid process compared with schizophrenic process [Meissner], 7(4):611-631, 1981; [Magaro], 7(4):632-661, 1981.

Persecutory delusions in [Kendler], 6(1):1-3, 1980; [Kendler], 7(4):594-610, 1981.

Premorbid adjustment and [Cromwell], 7(4):674-688, 1981; [Ritzler], 7(4):710-728, 1981.

Prognosis of [Kendler], 6(1):1-3, 1980; [Ritzler], 7(4):710-728, 1981.

Psychophysiologic findings in [Gruzelier], 7(4):662-673, 1981.

Treatment of [Ritzler], 7(4):710-728, 1981.

**Perceptual aberration** [Chapman], 6(3):476-489, 1980; [Chapman], 6(4):639-653, 1980.

### Pervasive developmental disorders

DSM-III multi-axial approach to classification of disorders of childhood [DeMyer], 7(3):388-451, 1981.

### Pharmacotherapy

- Characteristics of responders/nonresponders [Davis], 6(1):70-87, 1981.
- Depressive syndromes in response to [Hartmann], 6(3):536-543, 1980.
- Effects on paranoids [Ritzler], 7(4):710-728, 1981.
- Efficacy of (literature review) [Davis], 6(1):70-87, 1980; (discussion) [Goldberg], 6(1):117-121, 1980.
- In infantile autism and disorders of childhood [DeMyer], 7(3):388-451, 1981.

Informed consent by patient to undergo long-term therapy [Linden], 7(3):372-378, 1981.

Interaction with psychosocial treatment [Mosher], 6(1):8-9, 1980; [Schooler], 6(1):131-134, 1980.

Low dose responders [Young], 6(1):88-101, 1980.

Prevention of relapse [Hartmann], 6(3):536-543, 1980.

Side effects [Hartmann], 6(3):536-543, 1980.

Side effects as reported and understood by patients [Linden], 7(3):372-378, 1981.

Therapeutic effects as perceived by patients [Linden], 7(3):372-378, 1981.

Use in outpatient setting [Hartmann], 6(3):536-543, 1980.

### Premorbid adjustment

As predictor of psychiatric outcome [Prentky], 6(1):139-148, 1980.

### Prognosis. See also Outcome.

- Childhood school behavior and home environment related to [Prentky], 6(1):139-148, 1980.
- In infantile autism [DeMyer], 7(3):388-451, 1981.
- In paranoid disorders [Kendler], 7(4):594-610, 1981; [Ritzler], 7(4):710-728, 1981.
- Psychiatric symptoms at first admission related to [Prentky], 6(1):139-148, 1980.

**Psychofeedback in the treatment of schizophrenia** [Marsh], 7(2):201-203, 1981.

### Psychophysiology

- In infantile autism (early onset psychoses) [James], 6(3):506-525, 1980.
- Lateralization findings in paranoid and nonparanoid schizophrenia [Gruzelier], 7(4):662-673, 1981; [Cromwell], 7(4):674-688, 1981.
- Measuring deviant eye tracking [Lykken], 7(2):204-205, 1981.
- Skin conductance responses in children at risk [Prentky], 7(2):281-291, 1981.

**Psychosocial treatment.** *See also*

Behavioral/educational treatment;  
Community support systems;  
Family treatment; Group therapy;  
Milieu therapy; Psychotherapy.

Effectiveness in schizophrenia (literature review) [Mosher], 6(1):10-41, 1980; (discussion) [Goldberg], 6(1):117-121, 1980; (discussion) [Klein], 6(1):122-130, 1980; [Schooler], 6(1):131-134, 1980; [Schulz], 6(1):135-138, 1980.

Interaction with pharmacotherapy [Mosher], 6(1):8-9, 1980.

Psychosocial rehabilitation entry project [Brey], 7(3):522-526, 1981.

**Psychotherapy, individual**

Characteristics of schizophrenic patients in long-term therapy [Beck], 7(2):241-247, 1981.

Description of therapeutic relationship [Benedetti], 6(4):633-638, 1980.

Effectiveness in schizophrenia (literature review) [Mosher], 6(1):10-41, 1980; (discussion) [Klein], 6(1):122-130, 1980; (discussion) [Schulz], 6(1):135-138, 1980.

With paranoids [Ritzler], 7(4):710-728, 1981.

**Psychotic experiences.** *See also* Autobiographical accounts.

Physical anhedonia, perceptual aberration, and psychosis proneness [Chapman], 6(3):476-489, 1980; [Chapman], 6(4):639-653, 1980.

Scales for rating [Chapman], 6(3):476-489, 1980; [Chapman], 6(4):639-653, 1980.

**Public attitudes.** *See* Community attitudes toward the mentally ill.**Q****Quality of life**

Checklist to assess quality of life in schizophrenic outpatients [Malm], 7(3):479-487, 1981.

**R****Reaction time, cross-modal**

[Mannuzza], 6(4):654-675, 1980.

**Rehabilitation of discharged patients**

(letter) [Easton], 6(4):553-554, 1980.

**Research grants**

National Institute of Mental Health, fiscal year 1979, 7(2):318-365, 1981.

**Research methodology**

Designs of clinical trials [Schooler], 6(1):131-134, 1980.

Planning of clinical psychiatric research [Grinker], 7(1):181-195, 1981.

Survey of use of psychotic control groups in research on schizophrenia [Ritzler], 7(4):729-735, 1981.

**Research in schizophrenia**

Clinical applications of findings [Schulz], 6(1):135-138, 1980.

**Residual schizophrenia** [Huber],

6(4):592-605, 1980.

**S****Schizoaffective psychoses**

Course of illness compared to bipolar affective disorders [Angst], 6(4):579-585, 1980.

Family-genetic study [Scharfetter], 6(4):586-591, 1980.

**Schizophrenia spectrum**

Adoption study findings concerning [Kessler], 6(3):404-416, 1980.

**Schizophrenic process**

Cognitive style [Magaro], 7(4):632-661, 1981.

Psychoanalytic and experimental interpretations [Meissner], 7(4):611-631, 1981.

**Schizophrenic subtypes**

Family-genetic study [Scharfetter], 6(4):586-591, 1980.

Group of hypotonic childhood schizophrenics [Cantor], 7(1):1-11, 1981.

**Schizotypal experiences.** *See* Psychotic experiences.**Schizotypal patients**

Attention and information processing deficits in [Braff], 7(3):499-508, 1981.

**Segmental set**

Implications of word association test findings for theory [Shakow], 6(4):676-685, 1980.

**Shakow, David**

In memoriam [Parloff], 7(3):383-384, 1981; [Garnezy], 7(3):385-387, 1981.

**Single room occupancy (SRO) hotels**

Social networks in [Sokolovsky], 7(1):109-116, 1981.

**Social causes of schizophrenia**

British studies of [Wing], 6(4):556-565, 1980.

**Social networks**

As variables in developing scale of social relationships [McFarlane], 7(1):90-100, 1981.

Case study of network intervention in family of schizophrenic [Pattison], 7(1):135-143, 1981.

Characteristics of networks of mentally ill in peasant society [Westermeyer], 7(1):125-134, 1981.

Characteristics related to well-being of normals [Phillips], 7(1):117-124, 1981.

Concept in schizophrenia research [Hammer], 7(1):45-57, 1981; [Beels], 7(1):58-72, 1981; [Wolfe], 7(1):173-177, 1981.

In high-risk populations [Hirsch], 7(1):164-172, 1981.

In interactional model of schizophrenic disorders [Marsella], 7(1):152-163, 1981.

In single room occupancy (SRO) hotels [Sokolovsky], 7(1):109-116, 1981.

Network analysis profile and network mapping [Sokolovsky], 7(1):109-116, 1981.

Pattison Psychosocial Kinship Inventory [Pattison], 7(1):135-143, 1981.

Schizophrenia viewed as a network crisis [Lipton], 7(1):144-151, 1981.

#### **Social psychiatry**

British contributions to [Wing], 6(4):556-565, 1980.

#### **Social Relationship Scale**

Methodological issues in scale development [McFarlane], 7(1):90-100, 1981.

**Social skills training** (literature review) [Wallace], 6(1):42-63, 1980; (discussion) [Goldberg], 6(1):117-121, 1980.

#### **Social support**

In interactional model of schizophrenic disorders [Marsella], 7(1):152-163, 1981.

Meaning considered in relationship to social networks and schizophrenia [Hammer], 7(1):45-57, 1981; (discussion) [Wolfe], 7(1):173-177, 1981; (discussion) [Huessy], 7(1):178-180, 1981.

Measures used in schizophrenia research reviewed [Beels], 7(1):58-72, 1981.

Operationally defined as "intimate psychosocial network" [Pattison], 7(1):135-143, 1981.

#### **Stress**

Causal significance of stressful life events in schizophrenia [Dohrenwend], 7(1):12-23, 1981; (discussion) [Wolfe], 7(1):173-177, 1981; (discussion) [Huessy], 7(1):178-180, 1981.

Community survey assessing relation of stressful life events to schizophrenia [Lin], 7(1):73-89, 1981.

Operational definitions in schizophrenia research [Spring], 7(1):24-33, 1981.

Stress states in interactional model of schizophrenic disorders [Marsella], 7(1):152-163, 1981.

#### **T**

**Tardive dyskinesia.** See Dyskinesia, tardive.

**Teaching schizophrenic inpatients about schizophrenia** [Pilssecker], 7(3):379-382, 1981.

**Total institution** [Shadish], 7(3):488-498, 1981; (discussion) [Carling], 7(4):574-579, 1981; (rejoinder) [Shadish], 7(4):580-585, 1981.

#### **Treatment effectiveness**

Research designs of evaluative studies [Schooler], 6(1):131-134, 1980.

#### **Twin studies**

Concordance rates for schizophrenia [Kessler], 6(3):404-416, 1980. In Nordic countries [Kringlen], 6(4):566-578, 1980.

#### **V**

**Viral factors in schizophrenia** [Bowers], 6(3):393-403, 1980.

#### **W**

#### **Word association**

Kent-Rosanoff association test and segmental set theory [Shakow], 6(4):676-685, 1980.